类风湿关节炎的常见药物基因组学研究进展
被引量:2
摘要
药物基因组学是药理学和遗传学的交叉学科,它通过研究基因结构多态性与不同药物反应之间的关系,解释由于个体之间的差异所表现出药物的不同治疗效果或者不良反应的发生,从而为患者或特定人群寻找“疗效肯定、不良反应小”的药物。最新研究显示,药物代谢的某些基因与疾病表型也存在一定的关系,因而药物基因组学研究具有重要的理论意义和广阔的应用前景。
出处
《中华风湿病学杂志》
CAS
CSCD
北大核心
2012年第12期841-844,共4页
Chinese Journal of Rheumatology
基金
基金项目:国家自然科学基金面上项目(81172850)
参考文献22
-
1Davis LA, Cannon GW, Pointer LM, et al. Methotrexate use,MTHFR polymorphisms and traditional risk factors in predictingcardiovascular events in elderly males with rheumatoid arthritis(RA). Ann Rheum Dis, 2011, 70: 92-93.
-
2Wessels JAM, van der Kooij SM, Cessie SL, et al. A clinicalpharmacogenetic model to predict the efficacy of methotrexatemonotherapy in recent-onset rheumatoid arthritis. ArthritisRheum, 2007 , 56: 1765-1775.
-
3Fisher MC, Cronstein BN. Meta-analysis of methylenetetrahydrofo-late reductase (MTHFR) polymorphisms affecting methotrexatetoxicity. J Rheumatol, 2009, 36: 539-545.
-
4肖会,徐建华,周小妹,张志华,申世华,李迎伟.类风湿关节炎患者亚甲基四氢叶酸还原酶基因多态性与甲氨蝶呤治疗的相关性研究[J].安徽医科大学学报,2011,46(11):1157-1161. 被引量:2
-
5Hayashi H, Fujimaki C, Daimon T, et al. Genetic polymor-phisms in folate pathway enzymes as a possible marker for pre-dicting the outcome of methotrexate therapy in Japanese patientswith rheumatoid arthritis. J Clin Pharm Ther, 2009, 34: 355-361.
-
6Straaten RJ, Wessels JA, Vries-Bouwstra JK, et al. Exploratoryanalysis of four polymorphisms in human GGH and FPGS genesand their effect in methotrexate-treated rheumatoid arthritis pa-tients. Phannacogenomics, 2007, 8: 141-150.
-
7Chen J, Chen L,Mao N, et al. Association of the MDR1 3435polymorphism in patients with refractory rheumatoid arthritis in aChinese population. Rheumatol Int, 2012,32: 3127-3130.
-
8Mikuls TR, Levan T, Gould KA, et al. Impact of interactions ofcigarette smoking with NAT2 polymorphisms on rheumatoidarthritis risk in African Americans. Arthritis Rheum, 2012,64:655-664.
-
9Taniguchi A, Urano W, Tanaka E,et al. Validation of the asso-ciations between single nucleotide polymorphisms or haplotypesand responses to disease-modifying antirheumatic drugs in pa-tients with rfieumatoid arthritis: a proposal for prospective phar-macogenomic study in clinical practice. Pharmacogenet Ge-nomics, 2007, 17: 383-390.
-
10Behrens F, Koehm M,Burkhardt H. Update 2011: leflunomidein rheumatoid arthritis: strengths and weaknesses. Curr OpinRheumatol? 2011, 23: 282-287.
二级参考文献41
-
1Jones G, Halbert J, Crotty M, et al. The effect of treatment on ra- diological progression in rheumatoid arthritis : a systematic review of randomized placebocontrolled trials [ J ]. Rheumatology ( Oxford ),2003,42( 1 ) :6 - 13.
-
2Wessels J A,de Vries-Bonwstro J K,Heijmans B T,et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associ- ated with single-nucleotide polymorphisms in genes coding for fo- late parthway enzymes [ J ]. Arthritis Rheum, 2006,54 ( 4 ) : 1087 -95.
-
3Weisman M H, Furst D E, Park G S, et al. Risk genotype in folate- dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis [ J ]. Arthritis Rheum ,2006,54 (2) :607 - 12.
-
4Ogino S, Wilson R B. Genotype and haplotype distributions of MTHFR 677C > T and 1298A > C single nucleotide polymor- phisms : a meta-analysis [ J ]. J Hum Genet,2003,48 ( 1 ) : 1 - 7.
-
5Kim S K,Jun J B, El-Sonemy A, et al. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate [J]. J Rheumatol,2006,33(7) :1266 -74.
-
6Urano W,Taniguchi A, Yamanaka H, et al. Potymorphisms in the methylenetetrahydrofolate reductase gene were associated with the efficacy and the toxicity of mcthotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus methylenetetra- hydrofolate reductase gene and haplotype analyses [ J ]. Pharmaco- genetics ,2002,12 ( 3 ) : 181 - 2.
-
7Fisher M C,Cronstein B N. Meta-analysis of methylenetetrahydro- folate reductase ( MTHFR ) polymorphisms affecting methotrexate toxicity [ J ]. J Rheumatol,2009,36 ( 3 ) : 539 - 45.
-
8Hughes L B, Beasley T M, Patel H, et al. Racial or ethnic differ- ences in allele frequencies of single - nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis[ J]. Ann Rheum Dis,2006,65 (9) :1213 -8.
-
9Kumagaik K, Hiyama K, Oyama T, et al. Polymorphisms in the thy- midylate synthase and MTHFR genes and sensitivity to the low- dose methotrexate therapy in patients with rheumatoid arthritis[ J ]. Int J Mol Med,2003,11 ( 5 ) : 593 - 600.
-
10Taraborelli M, Andreoli L, Archetti S, et al. Methylenetetrahydrofo- late reductase polymorphisms and methotrexate:no association with response to therapy nor with drug-related adverse events in an Ital- ian population of rheumatic patients [ J ]. Clin Exp Rheumatol, 2009,27 ( 2 ) :499 - 502.
共引文献7
-
1夏晓茹,王坚,王博,陈培荣,秦韦,朱小春.英夫利西单抗治疗炎性关节炎不良事件分析[J].中国新药与临床杂志,2012,31(9):565-568. 被引量:1
-
2安梅,孙和炎,卢锦森,马中飞,纵何香,叶桂萍,郭利梅,何舒宁,陈晓宇.基质金属蛋白酶1及其抑制剂在白藜芦醇治疗佐剂性关节炎中的表达[J].安徽医科大学学报,2014,49(6):701-705. 被引量:4
-
3陈孟林,文集,赵毅,刘毅.肿瘤坏死因子-α拮抗剂治疗类风湿关节炎的药物基因组学研究进展[J].中华风湿病学杂志,2019,23(1):67-70. 被引量:5
-
4李芬,陈进伟,高洁生.生物组学技术在肿瘤坏死因子-α拮抗剂治疗类风湿关节炎疗效预测中的应用[J].中华风湿病学杂志,2014,18(10):713-716. 被引量:1
-
5李丹,耿玲玲,冯媛,李小青.强克治疗幼年特发性关节炎48例对照观察[J].陕西医学杂志,2016,45(9):1220-1221. 被引量:1
-
6李芬.类风湿关节炎的精准医学研究:任重而道远[J].中华风湿病学杂志,2016,20(9):577-579. 被引量:9
-
7崔永建,张红霞,王英,李艳.中药熏蒸联合InfIiximab治疗类风湿性关节炎疗效及与TNF-α基因-238位点单核苷酸多态性的相关性[J].世界中医药,2016,11(8):1443-1446. 被引量:3
同被引文献48
-
1Van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue[J]. Ann Rheum Dis, 2007, 66 : 849-851.
-
2Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis[J]. Ann Rheum Dis, 2009, 68: 1739-1745.
-
3Miossec P, Verweij CL, Klareskog L, et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies[J]. Ann Rheum Dis, 2011, 70: 1713-1718.
-
4Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor-c (TNF-ct) promoter -308 G/A and response to TNF-ct blockers in rheumatoid arthritis: a meta-analysis[J]. Mod Rheumatol, 2013, 23: 489-45.
-
5Kang CP, Lee KW, Yoo DI, et al. The influence of a poly- morphism at position -857 of e tumour necrosis factor gene on clinical response to etanercept therapy in rheumatoid arthritis[J]. Rheumatology, 2005, 44: 547-552.
-
6Miceli RC, Comets E, Verstuyft C, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis[J]. Ann Rheum Dis, 2008, 67: 478-484.
-
7Pavy S, Toonen E J, Miceli RC, et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response t TNF alpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis[J]. Ann Rheum 010, 69: 1022-1028.
-
8Ongaro A, de Mattei M, Pellati A, et al. Can tumor necrosis factor receptor lI gene 676T >G polymorphism predict the re- sponse grading to anti-TNF ilpha therapy in rheumatoid arthritis? [J]. Rheumatol Int, 2008, 28: 901-908.
-
9Criswell LA, Lum RF, Turner KN, et al. The influence of" genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with metho- trexate or etanercept[J]. Arthritis Rheum, 2004, 50: 2750-2756.
-
10Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumor necrosis factor response in rheumatoid arthritis[J]. Ann Rheum Dis, 2009, 68: 69-74.
二级引证文献10
-
1李芬.类风湿关节炎的精准医学研究:任重而道远[J].中华风湿病学杂志,2016,20(9):577-579. 被引量:9
-
2张惠琴,丰航,范志勇,党媛,呼延玲.沙利度胺联合甲氨喋呤与羟氯喹治疗类风湿关节炎的疗效分析[J].现代生物医学进展,2017,17(15):2949-2952. 被引量:8
-
3周心怡,骆耐香.Th17细胞及其相关细胞因子在类风湿性关节炎中的作用[J].国际免疫学杂志,2018,41(2):217-221. 被引量:19
-
4李光耀,周艳华,何彦春,邓志军,张宜,钟明,廖川.周祖山运用雷公藤治疗类风湿关节炎经验[J].中医药导报,2019,25(18):126-128. 被引量:3
-
5夏晴,纪羽婷,刘海亮,宋武琦.类风湿关节炎动物模型研究进展[J].中国比较医学杂志,2020,30(11):107-113. 被引量:19
-
6王姣姣,陈育松.隔物温和灸治疗寒湿痹阻型类风湿性关节炎的临床观察[J].中国中医药科技,2021,28(2):266-268. 被引量:5
-
7宋献美,李兵杰,张艳燕,葛文静,王慧森,李更生,梁瑞峰.防风石油醚提取物对胶原诱导型关节炎大鼠P38 MAPK磷酸化和AQP-1表达的影响[J].中药药理与临床,2021,37(5):80-85. 被引量:4
-
8赵敏,曾照富.自拟小柴胡汤中药溻渍联合红外线理疗仪治疗风寒湿痹证类风湿关节炎的效果[J].河南医学研究,2022,31(23):4373-4376.
-
9张敏,王海东,史恒蔚.基于“无湿不成痹”理论探讨脾与类风湿关节炎的相关性[J].风湿病与关节炎,2023,12(5):38-41. 被引量:1
-
10吕柳,马玉草,黄正慧,刘春平,朱华超,朱振红,方锦颖,王艺文,刘明煊,王海隆.从精准医学与辨证论治初探类风湿关节炎的个体化诊疗[J].时珍国医国药,2024,35(1):154-156.
-
1为特定人群研发药品[J].中国卫生,2014(6):65-65.
-
2李军,彭向前,张鉴.药物基因组学与临床合理用药[J].中国药事,2006,20(5):288-289. 被引量:2
-
3黄青,阿基业,周国华.基于药物代谢组学的个体化医疗研究进展[J].药学学报,2014,49(11):1491-1497. 被引量:6
-
4周斌,刘宏,殷明.哮喘药物的基因组学研究进展[J].中国临床药理学杂志,2003,19(1):63-66. 被引量:2
-
5韩佳音,吴磊.住院患者703例医院感染横断面调查与分析[J].中国冶金工业医学杂志,2005,22(5):567-568.
-
6黄剑.心衰与基因的研究进展[J].浙江临床医学,2010,12(3):321-322.
-
7李云法.阿奇霉素致心血管系统不良反应事件的临床分析[J].临床医药文献电子杂志,2015,2(26):5388-5388. 被引量:4
-
8创伤后抗菌药物预防性应用专家共识[J].中华急诊医学杂志,2016,25(10):1224-1228. 被引量:26
-
9方健.长期服用阿司匹林要注意什么[J].健康博览,2017,0(3):42-42.
-
10贾汉.基因与疾病研究进展[J].地方病通报,2002,17(1):80-82.